biotech · Recurrent Plasma Cell Myeloma · Anal Cancer Metastatic · ONCY
Oncolytics Biotech
ONCOLYTICS BIOTECH INC
Oncolytics Biotech clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 4350 Executive Dr, 325, San Diego, California 92121, US
- Founded
- 1998
- Employees
- 46
- Programs
- 23
- Drugs
- 14
- Patents
- 66
Oncolytics Biotech projects
8 ClinicalTrials.gov programs sponsored by Oncolytics Biotech.
Oncolytics Biotech has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Bortezomib
ONCOLYTICS BIOTECH INC
Recurrent Plasma Cell Myeloma
1 trial -
Carfilzomib
ONCOLYTICS BIOTECH INC
Recurrent Plasma Cell Myeloma
1 trial -
Lenalidomide or Pomalidomide
ONCOLYTICS BIOTECH INC
Multiple Myeloma
1 trial -
Pelareorep
ONCOLYTICS BIOTECH INC
Breast Cancer
1 trial -
REOLYSIN®
ONCOLYTICS BIOTECH INC
KRAS Mutant Metastatic Colorectal Cancer
1 trial -
REOLYSIN®
ONCOLYTICS BIOTECH INC
Malignant Glioma
1 trial -
REOLYSIN®
ONCOLYTICS BIOTECH INC
Muscle-invasive Transitional Cell Carcinoma of the Bladder
1 trial -
REOLYSIN®
ONCOLYTICS BIOTECH INC
Pancreatic Adenocarcinoma
1 trial
Frequently asked questions
How many clinical projects does Oncolytics Biotech have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.